Zenas BioPharma, Inc. (ZBIO)
NASDAQ: ZBIO · Real-Time Price · USD
21.87
+1.64 (8.11%)
Sep 15, 2025, 3:45 PM EDT - Market open
Zenas BioPharma Stock Forecast
Stock Price Forecast
The 7 analysts that cover Zenas BioPharma stock have a consensus rating of "Strong Buy" and an average price target of $32.29, which forecasts a 47.65% increase in the stock price over the next year. The lowest target is $19 and the highest is $45.
Price Target: $32.29 (+47.65%)
Analyst Consensus: Strong Buy
* Price targets were last updated on May 16, 2025.
Analyst Ratings
The average analyst rating for Zenas BioPharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | +37.17% | May 16, 2025 |
| Wedbush | Wedbush | Buy Initiates $35 | Buy | Initiates | $35 | +60.04% | Mar 20, 2025 |
| Guggenheim | Guggenheim | Strong Buy Reiterates $45 | Strong Buy | Reiterates | $45 | +105.76% | Mar 12, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | +37.17% | Mar 12, 2025 |
| Wolfe Research | Wolfe Research | Buy Initiates $19 | Buy | Initiates | $19 | -13.12% | Feb 4, 2025 |
Financial Forecast
Revenue This Year
10.20M
from 5.00M
Increased by 104.00%
Revenue Next Year
20.84M
from 10.20M
Increased by 104.27%
EPS This Year
-4.56
from -11.89
EPS Next Year
-4.32
from -4.56
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 10.5M | 89.3M | |
| Avg | 10.2M | 20.8M | |
| Low | 9.8M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 110.0% | 775.0% | |
| Avg | 104.0% | 104.3% | |
| Low | 96.0% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -4.38 | -2.91 | |
| Avg | -4.56 | -4.32 | |
| Low | -4.80 | -5.31 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.